Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

240-week entecavir maleate treatment in Chinese chronic hepatitis B predominantly genotype B or C.

Journal of viral hepatitis - 1 Oct 2022

Xu Jing-Hang, Fan Ya-Nan, Yu Yan-Yan, Si Chong-Wen, Zeng Zheng, Xu Zhong-Nan, Li Jun, Mao Qing, Zhang Da-Zhi, Tang Hong, Sheng Ji-Fang, Chen Xin-Yue, Ning Qin, Shi Guang-Feng, Xie Qing, Zhang Xi-Quan, Dai Jun

Abstract excerpt

This study aimed to evaluate the efficacy and safety of entecavir(ETV) versus ETV maleate in Chinese patients with chronic hepatitis B(CHB). This was a randomized, double-blind, double-dummy, controlled, multicentre study. Patients were randomly assigned to receive 48 weeks of treatment with 0.5 mg/day ETV (group A) or 0.5 mg/day ETV maleate (group B), then, all patients received treatment with 0.5 mg/day ETV...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to China

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to DNA, Viral

Share to Guanine

Share to Hepatitis B, Chronic

Share to Hepatitis B e Antigens

Share to Hepatitis B virus

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 35737855
DOI: 10.1111/jvh.13724
PMCID: PMC9545224

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

240-week entecavir maleate treatment in Chinese chronic hepatitis B predominantly genotype B or C.PMID 35737855Read ↗

Entecavir maleate versus entecavir in Chinese chronic hepatitis B predominantly genotype B or C: Results at week 144.Semantic proximity Read ↗

Long-term antiviral efficacy of entecavir and liver histology improvement in Chinese patients with hepatitis B virus-related cirrhosis.Semantic proximity Read ↗

Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial.Semantic proximity Read ↗

Use of entecavir for the treatment of complex forms of hepatitis B.Semantic proximity Read ↗

Efficacy of Different Nucleoside Analog Rescue Therapies for Entecavir-Resistant Chronic Hepatitis B PatientsSemantic proximity Read ↗

[Entecavir].Semantic proximity Read ↗

Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir.Semantic proximity Read ↗

Management of hepatitis B in China.Semantic proximity Read ↗

Sequential HBV Treatment With Tenofovir Alafenamide for Patients With Chronic Hepatitis B: Week 96 Results From a Real-world, Multicenter Cohort StudySemantic proximity Read ↗

Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infectionSemantic proximity Read ↗

Efficacy of entecavir treatment for up to 5 years in nucleos(t)ide-naïve chronic hepatitis B patients in real life.Semantic proximity Read ↗

Efficacy and Safety of Peginterferon α-2a and Entecavir Tenofovir in the Treatment of Chronic Hepatitis B Genotype C.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.